Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3404 - Prognostic value of systemic inflammatory biomarkers in patients with mCRPC treated with Abiraterone in pre-docetaxel setting


10 Sep 2017


Poster display session


Cytotoxic Therapy;  Prostate Cancer


Raffaele Ratta


Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370


R. Ratta1, E. Verzoni1, F. Pantano2, P. Grassi1, D. De Lisi2, A. Onorato2, M. Prisciandaro1, R. Montone3, F. de Braud1, D. Santini2, G. Procopio1

Author affiliations

  • 1 Medical Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 2 Medical Oncology, Campus Bio-Medico University, Rome/IT
  • 3 Trial Center, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 - Milan/IT


Abstract 3404


Systemic inflammatory biomarkers have shown a prognostic impact in several solid tumors. The aim of this study was to examine the prognostic role of baseline neutrophil-to-lymphocyte-ratio (NLR), platelet-to-lymphocyte-ratio (PLR) and lymphocyte-to-monocyte-ratio (LMR) and NLR, PLR and LMR changes at 1, 2 and 3 months in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with Abiraterone Acetate (AA) in pre-docetaxel setting.


We retrospectively included mCRPC pts treated with AA at two Italian hospitals from November 2012 to April 2017. NLR, PLR and LMR were evaluated at baseline and after 1, 2 and 3 months of treatment. The impact of NLR, PLR and LMR on progression-free survival (PFS) was evaluated by Cox regression analyses both in univariate and multivariate fashion. Other clinico-pathological factors, such as PSA baseline level, Time to CRPC, Gleason Score, Presence of Visceral Metastases and Bone Metastases Burden were included.


Fifty mCRPC pts treated with AA were evaluated. At univariate analysis, elevated baseline NLR and PLR were significantly associated with shorter median PFS (p = 0.01, hazard ratio [HR]=1.224 and p = 0.0001, HR = 1.013 respectively); after 1 month of treatment, NLR and PLR were significantly predictors of worst PFS (p = 0.03, HR = 1.320 and p = 0.02, HR = 1.012 respectively). After 2 and 3 months of treatment, only high PLR was associated with poor prognosis (p = 0.01, HR = 1.012 at month 2; p = 0.009, HR = 1.009 at month 3 respectively). LMR didn’t show any prognostic relevance. At multivariate analysis, only baseline PLR was independently associated with PFS (p = 0.006, HR = 1.013).


High baseline and early-assessed NLR and PLR during treatment with AA are associated with shorter PFS in mCRPC pts. PLR more than NLR may be considered as an early and easy-to-perform prognostic marker in this setting.

Clinical trial identification

Legal entity responsible for the study

Fondazione IRCCS Istituto Nazionale dei Tumori of Milan




E. Verzoni: Advisory boards: Jannsen. G. Procopio: Advisory board: Astellas, Bayer, Janssen and Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.